documented protocols
Dihexa: what is documented about dosing
The rodent studies state what they gave to rats and mice. That is the entire documented record, and it does not convert into an amount for a person.
- Primary sources Registry records and papers are read at the source, not through summaries. Read the methodology
- Every claim graded Each claim about what a compound does carries an evidence tier and a numbered citation. How grades derive
- Sells nothing No cart, no price, and no product page anywhere on this site. Conflict disclosure
- Corrections logged Errors are fixed and recorded in a permanent public log, never edited away. Corrections log
What follows is what published studies administered to animals, reported as that and nothing else.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
What this page reports, and what it does not
We report what has been documented. We do not prescribe what should be done.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
No trial established an amount of Dihexa for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.
Commonly cited protocols (extrapolated, not validated)
| Study | What was given | Frequency | Duration | Notes |
|---|---|---|---|---|
| Rodent behavioural studies | Amounts stated per kilogram of animal body weight in the source papers | As described in each study | As described in each study | Rats and mice. Two of the papers underpinning this literature carry publication flags, covered on the hub |
| Any human use | Nothing documented | Nothing documented | Nothing documented | No registered or published human study exists for this compound |
Commonly cited protocols (extrapolated, not validated) circulate for this compound in milligram amounts taken by mouth or under the tongue. They do not come from a study. There is no human study of this compound from which a figure could come.
Body-weight scaling from a rodent to a person is unreliable even between two species dosed by the same route with a well characterised drug. Here there is no human route, no human exposure measurement, and no pharmacokinetic bridge of any kind, so there is nothing to scale and nothing to scale it with.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
Our takeThere is no documented amount for a person and no way to derive one from what exists. That is the whole of it.,Talk to a licensed clinician about anything concerning your health.
Main routes people compare
By mouth
The route the compound is generally sold for. No published study has measured what happens to it in a person by this route or any other.
The routes used in animals
The rodent studies used the routes their authors chose for a laboratory animal. Those choices were made to answer a question about a rat, and they carry no implication for a person.
What is said about cycle length and timing
No cycle length appears anywhere in the published record for this compound, because no study of a person has ever been run to establish one.
Talk to a licensed clinician about anything concerning your health.
What has been measured about safety
A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about Dihexa, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.
Frequently asked questions
Is there an established dose for dihexa?
No. No human study of this compound has been published or registered, so no amount has been established and there is no measurement from which one could be derived.
Where do the figures circulating online come from?
Not from a study of people, because none exists. This site does not reproduce them as guidance.
Can the rodent amounts be scaled to a person?
No. Body-weight scaling between species is unreliable even for well characterised drugs given by the same route, and here there is no human route, no exposure measurement and no pharmacokinetic bridge to scale across.
References
- Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014. PMID 25187433 DOI 10.1124/jpet.114.218735 Retracted April 2025 (retraction notice PMID 40312093); carried an Expression of Concern from September 2021 (J Pharmacol Exp Ther 2021;378(3):311). Cited here as the record of what was claimed and what happened to it, not as evidence.
- McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013. PMID 23055539 DOI 10.1124/jpet.112.199497 Carries an Expression of Concern published September 2021 (J Pharmacol Exp Ther 2021;378(3):313), still standing as read on 23 August 2026.
- Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021. PMID 34827486
- Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. J Huntingtons Dis. 2024. PMID 38489193
- Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015. PMID 25937370
- Mathapati S, Siller R, Impellizzeri AA, Lycke M, Vegheim K, Almaas R, Sullivan GJ. Small-Molecule-Directed Hepatocyte-Like Cell Differentiation of Human Pluripotent Stem Cells. Curr Protoc Stem Cell Biol. 2016. PMID 27532814
- Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015. PMID 25455861 A review by the originating group.
- Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. 2018. PMID 29733881
- Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2015. PMID 25649658 A review by the originating group.
- Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402]. J Pharmacol Exp Ther. 2025. PMID 40312093 DOI 10.1016/j.jpet.2025.103567 Read via PubMed on 23 August 2026; the notice carries no abstract there and the publisher page did not return a document, so the stated reason for the retraction was not obtained.
- ClinicalTrials.gov. Registry sweep for dihexa, PNB-0408 and N-hexanoic-Tyr-Ile-(6) aminohexanoic amide across the intervention and free-text fields, run through the v2 API on 23 August 2026. No record returned at any phase, in any country, for any indication. ClinicalTrials.gov. 2026. ClinicalTrials.gov
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. The category 2 table carries the row Dihexa acetate, reading: FDA has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration; FDA lacks important information regarding any safety issues raised by dihexa acetate, including whether it would cause harm if administered to humans. Page content current as of 22 April 2026, fetched with a browser user agent and read on 23 August 2026. Appended on 2026-08-23, when this page's regulatory section was corrected: it had stated that no agency had evaluated this compound. FDA human drug compounding. 2026. FDA category 2 list